Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-06-14
2005-06-14
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S246100, C424S184100, C424S780000, C424S115000, C424S522000, C424S431000, C424S401000, C424S404000, C424S409000, C424S078050, C424S078020, C424S078070, C424S093460, C424S093462, C424S093470, C514S887000, C435S252310
Reexamination Certificate
active
06905692
ABSTRACT:
The present invention discloses compositions derived from an isolatedBacillusspecies, spores, or an extracellular product ofBacillus coagulanscomprising a supernatant or filtrate of a culture of saidBacillus coagulansstrain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolatedBacillusspecies, spores, or an extracellular product ofBacillus coagulanscomprising a supernatant or filtrate of a culture of saidBacillus coagulansstrain. In addition, the present invention also discloses compositions, methods of treatment, and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, comprising an extracellular product ofPseudomonas lindbergiicomprising a supernatant or filtrate of a culture of saidPseudomonas lindbergiistrain.
REFERENCES:
patent: 4062943 (1977-12-01), Lindberg
patent: 4110477 (1978-08-01), Naruse et al.
patent: 4323651 (1982-04-01), Long
patent: 4790989 (1988-12-01), Hunter et al.
patent: 5079164 (1992-01-01), Kirkovits et al.
patent: 5176911 (1993-01-01), Tosi et al.
patent: 5431924 (1995-07-01), Ghosh et al.
patent: 5439678 (1995-08-01), Dobrogosz et al.
patent: 5472713 (1995-12-01), Fein et al.
patent: 5540920 (1996-07-01), Vinopal et al.
patent: 5698227 (1997-12-01), Rivlin
patent: 6103246 (2000-08-01), Tisdale et al.
patent: 6261577 (2001-07-01), Kessler
patent: 6312703 (2001-11-01), Orthoefer
patent: 6416772 (2002-07-01), Van Engelen et al.
patent: 6461607 (2002-10-01), Farmer
patent: 6531126 (2003-03-01), Farmer
patent: 6579543 (2003-06-01), McClung
patent: 6645506 (2003-11-01), Farmer
patent: 2001/0033838 (2001-10-01), Farmer
patent: 2003/0003107 (2003-01-01), Farmer
patent: 2003/0031659 (2003-02-01), Farmer
patent: 2003/0124104 (2003-07-01), Farmer
patent: 2003/0143262 (2003-07-01), Brusk et al.
patent: 2003/0170334 (2003-09-01), Farmer
patent: 06166623 (1994-06-01), None
patent: WO 92/08470 (1992-04-01), None
patent: WO 93/14187 (1993-07-01), None
patent: WO 94/11492 (1994-05-01), None
patent: WO 97/02846 (1997-01-01), None
patent: WO 98/47374 (1998-10-01), None
patent: WO 98/54982 (1998-12-01), None
patent: WO 00/07606 (2000-02-01), None
patent: WO 00/10582 (2000-03-01), None
patent: WO 00/61201 (2000-10-01), None
Snowden et al, Inflammopharmacology, 1997, 5:127-132.
Czaczyk et al, Acta Microbological Polonica, 2002, 51/3:275-283.
Sussman, et al., 1986. Clinical manifestations and therapy ofLactobacillus endocarditis:report of a case and review of the literature.Rev Infect. Dis. 8:771-776.
Hata, et al., 1988. Meningitis caused byBifidobacteriumin an infant.Pediatr. Infect. Dis. 7:669-671.
Reid, et al, 1990. Is there a role forlactobacilliin prevention of urogenital and intestinal infections?Clin. Microbiol. Rev. 3: 335-344.
Gibson, et al., 1995. Selective stimulation ofbifidobacteriain the human colon by oligofructose and inulin.Gastroenterology 106: 975-982.
Saavedra, 1994. Feeding ofBifidobacterium bifidumandStreptococcus thermophilusto infants in hospital for prevention of diarrhoea and shedding of rotavirus.Lancet 344: 1046-109.
Mitchell, 1998. Rearming in the fight against bacteria.Lancet 352: 462-463.
Shannon, 1998. Multiple-antibiotic-resistant salmonella.Lancet 352: 490-491.
Thomason, et al, 1991. Bacterial vaginosis: current review with indications for asymptomatic therapy.Am. J. Obstet Gynecol. 165: 1210-1217.
Marsh, 1993. Antimicrobial strategies in the prevention of dental caries.Caries Res. 27: 72-76.
Hill & Embil, 1986. Vaginitis: current microbiologic and clinical concepts.Can. Med. Assoc. J. 134: 321-331.
Fuller, R., 1989. Probiotics in man and animals.J. Appl. Bacteriol. 66: 365-378.
Nakamura, et al., 1988. Taxonomic study forBacillus coagulansHammer 1915.J. Systematic Bacterio. 38: 63-73.
Winberg, et al., 1993. Pathogenesis of urinary tract infection-experimental studies of vaginal resistance to colonization.Ped. Nephrol. 7: 509-514.
Zemtsov et al., “Moisturizing and cosmetic properties of emu oil: A pilot double blind study”, Australasian J. Dermatol. 37:159-162, 1996.
Hodges et al., “Potential biocontrol of sclerotina homeocarpa and bipolaris sorokiniana on the phylloplane of Poa pratensis with strains ofPseudomonassp.”, Plant Path., 43:500-506, 1994.
Ganeden Biotech, Inc.
Minnifield N. M.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Topical compositions containing probiotic bacillus bacteria,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical compositions containing probiotic bacillus bacteria,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical compositions containing probiotic bacillus bacteria,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477039